#### **NOVOGEN LIMITED**

(ASX: NRT)



18 March 2016

Mrs Violetta Codreanu Adviser, Listings Compliance (Sydney) ASX Compliance Pty Ltd 20 Bridge St, Sydney NSW 2000

By electronic lodgement

Dear Violetta.

#### **Appendix 3B – Issue of Options to Dr James Garner**

Please find attached an Appendix 3B in respect of the issue of 7,500,000 Options to Novogen Chief Executive Officer and Managing Director, Dr James Garner.

The issue of Options was approved by the Shareholders at the General Meeting held today, 18 March 2016.

The issue was made in accordance with the Company's Employee Share Option Plan, which was approved by the Shareholders on 4 March 2015.

Yours faithfully,

**Lionel Mateo** 

**Company Secretary** 

# **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/oo, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$ 

Novo	Novogen Limited ("Novogen")		
ABN 37 06	3 259 754		
We (t	he entity) give ASX the following	g information.	
	<b>Part 1 - All issues</b> You must complete the relevant sections (attach sheets if there is not enough space).		
1	*Class of *securities issued or to be issued	Unlisted Options ( <b>Options</b> )	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	7,500,000 Options	

Name of entity

<sup>+</sup> See chapter 19 for defined terms.

Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

#### Α

Options 5,000,000
Exercise price \$0.1988
Commencement Date 1 February 2016

#### **Vesting Schedule**

(from Commencement Date)

- a) 750,000 6 months
- b) 750,000 1 year
- c) 750,000 18 months
- d) 750,000 2 years
- e) 2,000,000 3 years

#### **Exercise**

#### **Period**

For tranches on the second anniversary of the Commencement Date

For tranche on the third anniversary of the Commencement Date

#### В

Options 2,500,000
Exercise price \$0.2605
Commencement Date 1 February 2016

#### **Vesting Schedule**

(from Commencement Date)

a) 2,500,000 4 years

**Exercise** On the fourth anniversary of **Period** the Commencement Date

#### Option Period end date (for both A & B)

The earlier of:

- a) the date of termination of employment
- b) the date that is 5 years after the

Commencement date

Upon exercise, Options convert into ordinary shares which will rank pari passu with existing ordinary shares quoted on ASX.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	N/A
5	Issue price or consideration	Issued for nil consideration
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Options issued in accordance with the Employee Share Option Plan, approved by the Shareholders on 4 March 2015 and pursuant to shareholders' approval received on 18 March 2016
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	yes
6b	The date the security holder resolution under rule 7.1A was passed	12 November 2015
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	7,500,000	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
		[	
6i	Calculate the entity's remaining	Listing Rule 7.1: 7,814,262	
	issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market	Listing Rule 7.1A: 9,600,60	9
	Announcements	Total = 17,414,872	
		, ,	
7	+Issue dates	18 March 2016	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	10 March 2010	
		Number	+Class
8	Number and +class of all +securities quoted on ASX	429,733,982	Ordinary Shares
	(including the *securities in section 2 if applicable)	29,484,002	Equity options

9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	+Class
466,470	Unlisted options with exercise price of \$0.15 and expiry date of 16/12/2019.
199,521	Unlisted options with exercise price of \$0.15 and expiry date of 18/12/2019.
60,000,000	Unlisted convertible notes, with combined face value of \$1,500,000
25,875,000	Unlisted options with exercise price of \$0.40 and expiry date of 30 June 2020
5,190,000	Unlisted options with exercise price of \$0.40 and expiry date of 30 June 2020
5,500,008	Unlisted options with exercise price of \$0.22 and expiry date of 16 November 2020
5,000,000	Unlisted options with exercise price of \$0.1988 and expiry date of 1 February 2021
2,500,000	Unlisted options with exercise price of \$0.2605 and expiry date of 1 February 2021
	ı
N/A	

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

## Part 2 - Pro rata issue

11	Is security holder approval N required?	T/A
12	Is the issue renounceable or non-renounceable?	T/A
13	Ratio in which the *securities N will be offered	T/A
14	*Class of *securities to which the Offer relates	T/A
	+D 1 1 1	
15	*Record date to determine N	/A

<sup>+</sup> See chapter 19 for defined terms.

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 6 04/03/2013

28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

<sup>+</sup> See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	N/A
33	<sup>+</sup> Issue		N/A
		uotation of securitie	<b>S</b> oplying for quotation of securities
34	Type (tick o	of *securities one)	
(a)		*Securities described in Part	1
(b)		All other <sup>+</sup> securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities	
Entities that have ticked box 34(a) Additional securities forming a new class of securities			
Tick to locum		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36			y securities, a distribution schedule of the additional umber of holders in the categories
37		A copy of any trust deed for	the additional <sup>+</sup> securities

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Number	+Class

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: \_\_\_\_\_\_Date: \_\_\_\_18/03/2016.....

(Director/Company secretary)

Print name: Lionel Mateo

== == == ==

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	251,344,150	
<ul> <li>Add the following:         <ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> </ul> </li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period         <ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid +ordinary securities cancelled during that 12 month period</li> </ul>	-	
" <b>A</b> "	377,983,982	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	56,697,597	
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule	
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	Placement as announced on 21 April 2015, issuing 42,313,335 ordinary shares.	
Under an exception in rule 7.2	6,570,000 options to placement agent regarding the placement of securities announced on 21 April 2015	
Under rule 7.1A	amouniou on 217 pm 2010	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	48,883,335	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	B"] to calculate remaining	
"A" x 0.15	56,697,597	
Note: number must be same as shown in Step 2		
Subtract "C"	48,883,335	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	7,814,262	
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	377,983,982	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	37,798,398	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Securities issued on 19/12/2014 18,761,124	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	Securities issued on 24/04/2015 9,436,665	
"E"	28,197,789	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	37,798,398
Note: number must be same as shown in Step 2	
Subtract "E"	28,197,789
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	9,600,609
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.